Similar Search Results

Pricing, Consumption and Competition in Pharmaceutical Drugs

Costa, Eduardo - 2020

pharmaceuticals, induce drug substitution from branded to generics drugs and enhance competition. In these systems, patients co …

Persistent link: https://www.econbiz.de/10012827731

Pharmaceutical Pricing and Reimbursement Policies in Mexico

Moi͏̈se, Pierre - 2007

price regulation. It notes that retail prices for pharmaceuticals are relatively high, although proximity to the United … question the sustainability of financing pharmaceuticals in Mexico. It also contributes to greater inequality, although a new … unintended side-effect of the loss of low cost, non-bioequivalent drugs may be higher average prices for pharmaceuticals. …

Persistent link: https://www.econbiz.de/10012446729

Regulation of pharmaceutical prices : evidence from a reference price reform in Denmark

Kaiser, Ulrich; Mendez, Susan J.; Rønde, Thomas - 2010

On April 1, 2005, Denmark changed the way references prices, a main determinant of reimbursements for pharmaceutical purchases, are calculated. The previous reference prices, which were based on average EU prices, were substituted to minimum domestic prices. Novel to the literature, we estimate...

Persistent link: https://www.econbiz.de/10008660633

On the design of equity-oriented pharmaceutical copayments

González, Paula - In: SERIEs : Journal of the Spanish Economic Association 11 (2020) 2, pp. 179-202

In this paper, we propose a new approach to address the problem of designing pharmaceutical copayments. The rationale for positive copayments in our setting lies in the presence of budgetary constraints and, hence, in the need to raise funds in order to finance the costs of the treatments. We...

Persistent link: https://www.econbiz.de/10012240615

The impact of additive or substitutive clinical study design on the negotiated reimbursement for oncology pharmaceuticals after early benefit assessment in Germany

Dintsios, C. M.; Beinhauer, I. - In: Health economics review 10 (2020) 7, pp. 1-25

Background: We analysed the impact of clinical study design for oncological pharmaceuticals on the subsequent price … Health Insurance Funds. The analysis was conducted for all oncology pharmaceuticals that underwent the early benefit …. Further analyses should be performed when more oncology pharmaceuticals have passed the early benefit assessment. …

Persistent link: https://www.econbiz.de/10012291135

Consequences of disclosing clinical trial results : evidence from the food and drug administration amendments act

Bourveau, Thomas; Capkun, Vedran; Wang, Yin - 2020

We examine how the U.S. Food and Drug Administration Amendments Act (FDAAA) of 2007, which requires additional disclosures regarding clinical trial results, impacts information asymmetry between the disclosing pharmaceutical firm and capital market participants, the general public, academics,...

Persistent link: https://www.econbiz.de/10012295656

Hospitals and the generic versus brand-name prescription decision in the outpatient sector

Pruckner, Gerald J.; Schober, Thomas - 2016

Healthcare payers try to reduce costs by promoting the use of cheaper generic drugs. We show strong interrelations in drug prescriptions between the inpatient and outpatient sectors by using a large administrative dataset from Austria. Patients with prior hospital visits have a significantly...

Persistent link: https://www.econbiz.de/10011570769

Pharmaceutical M&A activity : effects on prices, innovation, and competition

Richman, Barak; Mitchell, Will; Vidal, Elena; Schulman, … - 2017

The rise of blockbuster pharmaceutical acquisitions has prompted fears that unprecedented market concentration will weaken competition. Two of the most prominent concerns focus on the upstream and downstream ends of the pharmaceutical industry: (1) the concern that these mergers will concentrate...

Persistent link: https://www.econbiz.de/10011721586

Advertising regulations in pharmaceutical markets : product versus enlightenment

Ishida, Junichiro; Takahara, Tsuyoshi - 2019

This paper analyzes the optimal content regulation of direct-to-consumer advertisement (DTCA) in a pharmaceutical market, with particular focus on the distinction between product and enlightenment advertisement. Firms are allowed to freely promote their own specific products under product DTCA,...

Persistent link: https://www.econbiz.de/10012024745

Die Rolle des Staates in der Impfstoffproduktion : technologische Restriktionen und ökonomische Ableitungen

Kirchhoff, Jasmina - 2021

Die Bundesregierung und die Europäische Kommission mussten in den letzten Wochen viel Kritik bezüglich ihrer Impfstoffbeschaffungsstrategie zur Eindämmung der Corona-Pandemie einstecken. Vor dem Hintergrund zu schleppend erscheinender Impfstofflieferungen und der zunehmenden Gefahr durch die...

Persistent link: https://www.econbiz.de/10012434819